Clinical Trial

DOTATATE PET for Meningioma Radiation Planning

Study acronym: DOTATATE-RT
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET
Trial Details
NCT Number NCT06937268
Lead Sponsor British Columbia Cancer Agency
Conditions Meningioma
Enrollment 36 participants
Start Date 2025-06
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-22